ClinicalTrials.gg
RecruitingNCT07469085Updated Apr 8, 2026

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Participants.

A Phase 1 interventional study of SV003 and Placebo in Healthy Participants, sponsored by Shanghai Synvida Biotechnology Co.,Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Shanghai Synvida Biotechnology Co.,Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of SV003 in healthy subjects.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

Shanghai Synvida Biotechnology Co.,Ltd. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI): 18.5 ≤ Chinese participants ≤ 30 kg/m², 18.5 ≤ Caucasian participants ≤ 32 kg/m²; additionally, male participants must have a body weight ≥ 50 kg, and female participants ≥ 45 kg;
  2. Healthy status: No evidence of active or chronic diseases in participants;
  3. Ability to participate in the study, willingness to provide written , and compliance with study requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of chronic diseases or currently presenting with systemic diseases;
  2. Subjects who have experienced a serious disease within 1 month prior to drug administration, or with any disease that may relapse immediately during or after the study;
  3. Subjects with designated examination results reaching a specified value;
  4. Subjects with abnormal laboratory test results deemed clinically significant by the investigator;
  5. Subjects positive for surface antigen (HBsAg), antibody (HCV-Ab), antibody (HIV-Ab), or Treponema pallidum antibody;
  6. Subjects with a history of drug abuse within the past 2 years, or with a positive urine drug screen on Day -1;
  7. Subjects with a history of alcohol dependence within the past 2 years, or with a positive breath alcohol test result on Day -1;
  8. Subjects with an average daily cigarette consumption of ≥ 5 cigarettes within 3 months prior to screening;
  9. Subjects who have donated blood or lost blood ≥ 400 mL within 3 months prior to drug administration, or donated blood or lost blood ≥ 200 mL within 1 month, or with a history of blood product use;
  10. Subjects with an allergic constitution, or with a history of allergy to the study drug, drugs of the same class or ;
  11. Subjects who have participated in clinical studies of drugs or medical devices within 3 months prior to drug administration;
  12. Female subjects with a positive pregnancy test during the screening period or on Day -1, or who are breastfeeding;
  13. Chinese female subjects who are or have an irregular menstrual cycle;
  14. Female subjects of , or male subjects whose female partners are of childbearing potential, who refuse to adopt reliable measures during the study and for 6 months after the last drug administration;
  15. Any other factors that the investigator deems may render a subject unsuitable for study participation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    SV003

    Drug: SV003

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugSV003

    SV003:Single-dose

  • DrugPlacebo

    Placebo : Single-dose

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Adverse event type, incidence, duration

    Time frame: Approximately 3 months

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    PK (Pharmacokinetics)

    Time frame: Approximately 3 months

  2. Peak time(Tmax)

    PK (Pharmacokinetics)

    Time frame: Approximately 3 months

  3. Area under the plasma concentration versus time curve (AUC)

    PK (Pharmacokinetics)

    Time frame: Approximately 3 months

  4. half-life(T1/2)

    PK (Pharmacokinetics)

    Time frame: Approximately 3 months

  5. Immunogenicity

    ADA(Anti-drug antibody)

    Time frame: Approximately 3 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2026
First posted
Mar 13, 2026
StartActual
Apr 4, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07469085
Lead sponsor
Shanghai Synvida Biotechnology Co.,Ltd.
Responsible party
Sponsor
First posted
Mar 13, 2026
Start date
Apr 4, 2026
Primary completion
Oct 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Qian Chen
Contact
xhzxyy@xh.sh.cn
86-021-36682212

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion